Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.5K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

807
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
807
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

500
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
500
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs.

Molecular cancer therapeutics·2025
Same author

Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy.

Expert opinion on drug discovery·2020
Same author

Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?

Antibodies (Basel, Switzerland)·2019
See all related articles

Related Experiment Video

Updated: Nov 7, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.8K

Tackling solid tumour therapy with small-format drug conjugates.

Mahendra P Deonarain1, Quinn Xue2

  • 1Antikor Biopharma Ltd, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG12FX, UK.

Antibody Therapeutics
|April 30, 2021
PubMed
Summary

Smaller antibody-drug conjugate (ADC) formats show promise for improved cancer treatment by enhancing drug delivery to solid tumors. Strategies focus on optimizing size and payload for better efficacy and safety.

Keywords:
antibody–drug conjugatefragmentsscaffoldssolid tumours

More Related Videos

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.5K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.9K

Related Experiment Videos

Last Updated: Nov 7, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.8K
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.5K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.9K

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • The pharmacokinetic-pharmacodynamic (PK-PD) relationship is critical for therapeutic efficacy, with tumor drug penetration being a key factor.
  • Antibody-drug conjugates (ADCs) have faced challenges, yet innovations are addressing limitations in drug delivery.
  • Immunoglobulin-based ADCs are prevalent, but smaller formats offer potential for enhanced cytotoxic payload delivery to solid tumors.

Purpose of the Study:

  • To review strategies for optimizing smaller ADC formats as viable drug delivery vehicles.
  • To explore methods for improving cytotoxic payload delivery and therapeutic windows in solid tumors.
  • To discuss approaches for increasing dosing frequency without inducing toxicity.

Main Methods:

  • Review of alternative technologies and strategies for smaller ADC formats.
  • Analysis of size optimization for enhanced therapeutic windows.
  • Examination of conjugation and half-life extension technologies for increased payload delivery.

Main Results:

  • Smaller ADC formats may offer a higher therapeutic window due to more rapid clearance.
  • Strategies are being employed to increase the amount of functional cytotoxic payload delivered.
  • Methods to extend dosing intervals without toxicity are under investigation.

Conclusions:

  • Optimizing the size and payload delivery of smaller ADC formats is crucial for their therapeutic success.
  • Further development in conjugation and half-life extension technologies can enhance ADC efficacy.
  • These advancements hold promise for more effective treatment of solid tumors with improved safety profiles.